Dear REMAP-CAP investigators,

In April and May many exciting things have happened. We have launched our European REMAP-CAP sub-website, where we post specific EU information regarding active domains, sites, important documents, a selection of REMAP-CAP media and an overview of the publications. The 3rd REMAP-CAP video is out explaining how we make a difference in clinical research. Also, new podcast episodes featuring Alistair Nichol and Derek Angus have been added to the series. Furthermore, we have welcomed new sites to our growing family and added new domains to the trial. And lastly, several manuscripts are published, and more in preparation. Have a look at the EU website to find out more and enjoy reading this newsletter!

You can follow us on social media and help us share the latest REMAP-CAP news. Thank you for being part of our #remapcapfamily and for helping us find the best treatment for CAP and COVID-19.

Lennie Derde
Chair of the European Regional Management Committee

Find new podcast episodes in collaboration with Rob Mac Sweeney from Critical Care Reviews on Spotify and iTunes

---

RECRUITMENT UPDATE

We are proud to announce that REMAP-CAP is currently (7th June 2021) active in 320 sites in 22 countries worldwide and a total of 7,608 unique patients have been included, of which 6,766 COVID-19 patients. These patients contributed to a total of 13,747 randomisations in the different domains.

Europe:
- 231 Active sites
- 5,273 Patient Inclusions
- 5,037 COVID-19 Patients
- 10,224 Randomizations
MEDIA CAMPAIGN

Through our social media (LinkedIn, Instagram and Twitter) we want to reach local investigators, research nurses, patients and their families and explain why we do research, who we are doing it for and share the work being done. Furthermore, we want you to get to know our remapcapfamily and what it feels like to be part of the trial.

If you have any ideas for our media campaign and would like to help, let us know! Feel free to contact us at eu.remapcap@umcutrecht.nl

Therapeutic Anticoagulation in Non-Critically Ill Patients with Covid-19

In hospitalized patients with COVID-19 who are not on organ support, using therapeutic anticoagulation with heparin increases the probability of survival to hospital discharge with reduced use of organ support.

17 May 2021
Preprint MedRxiv

ANNOUNCEMENTS

Two more WE4YOUs are coming up before the summer. All previous webinars can be viewed here. After summer the WE4YOUs will be every first Wednesday of the month.

Did you miss the PREPARE webinar about the beauty and efficiency of REMAP-CAP? Find the link here.

ECRAID (European Clinical Research Alliance on Infectious Diseases), was launched the 1st of March 2021. The goal of ECRAID is to establish a sustainable clinical research organisation and network for infectious diseases. The first of its kind, ECRAID will bring together clinical research in infectious diseases. REMAP-CAP is an integral part of ECRAID and the first study open to recruitment.

The 3rd REMAP-CAP video is out explaining how we make a difference in clinical research.

A BIG WELCOME

In April and May, we have welcomed 6 European sites to the family. We are excited about making a difference in the treatment of CAP and COVID-19 patients together. A big welcome to:

- Rijnstate Hospital, Arnhem, NL
- Centre Hospitalier de Melun, FR
- Medisch Centrum Leeuwarden, NL
- Centre Hospitalier de Dieppe, FR
- Universitair Medisch Centrum Groningen, NL
- Tartu University Hospital, Tartu, EE
The COVID-19 Antiviral domain within REMAP-CAP has been updated and is ready for take-off. The objective of this domain is to determine the effectiveness of different antiviral agents for COVID-19 patients. This domain previously compared hydroxychloroquine, lopinavir/ritonavir, and a combination of these agents compared against no antiviral. Another widely available and low-cost anti-parasitic medicine, ivermectin, has been promoted as being effective against SARS-CoV-2. Several in-vitro and animal model studies report that ivermectin has anti-viral activity against SARS-CoV-2 and anti-inflammatory activity in COVID-19.

Possible mechanisms are inhibition of SARS-CoV-2 replication, inhibition of nuclear import of host and viral proteins, and competition in binding with the host-receptor binding region of SARS-CoV-2 spike protein.

Several studies are available, but all are subject to multiple potential sources of bias, e.g. small sample size, various doses and schedules used, non-blinded, use of concomitant medications, severity of COVID-19 not well described, and study outcomes measures not clearly defined. Despite the pre-clinical uncertainty regarding the exact mechanism of action and potential confounders in the clinical data for effectiveness, the limited clinical data to date supports the possibility of benefit. Furthermore, clinical trials in COVID-19, to date, have reported a low occurrence of adverse effects.

Ivermectin needs to be tested in a larger (not single-centered) high-quality randomized trial. REMAP-CAP facilitates rapid evaluation of ivermectin. Therefore, we are excited to further investigate the potential for benefit of ivermectin for COVID-19 patients.

In this domain, both moderately- and severely-ill COVID-19 patients are randomised to:
1. No ivermectin (in combination with antiviral agents that are licensed and in standard care)
2. Ivermectin (the use of antiviral agents that are licensed for COVID-19 is permitted)

To learn more about the Antiviral domain and to participate in this domain, please contact us at eu.remapcap@umcutrecht.nl